| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 86 | 2021 | 220 | 11.060 |
Why?
|
| Atrial Fibrillation | 78 | 2023 | 398 | 7.210 |
Why?
|
| Heart Conduction System | 56 | 2017 | 270 | 4.670 |
Why?
|
| Heart Atria | 36 | 2021 | 171 | 3.790 |
Why?
|
| Electrocardiography | 45 | 2021 | 391 | 3.590 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 23 | 2018 | 96 | 3.000 |
Why?
|
| Pulmonary Veins | 30 | 2020 | 107 | 2.820 |
Why?
|
| Dogs | 69 | 2021 | 505 | 2.190 |
Why?
|
| Atrioventricular Node | 26 | 2018 | 69 | 2.080 |
Why?
|
| Accessory Atrioventricular Bundle | 7 | 2021 | 17 | 1.790 |
Why?
|
| Tachycardia | 19 | 2016 | 72 | 1.690 |
Why?
|
| Cardiac Pacing, Artificial | 36 | 2021 | 146 | 1.650 |
Why?
|
| Wolff-Parkinson-White Syndrome | 13 | 2021 | 23 | 1.570 |
Why?
|
| Body Surface Potential Mapping | 10 | 2012 | 24 | 1.560 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 16 | 2018 | 29 | 1.550 |
Why?
|
| Cardiac Catheterization | 18 | 2018 | 112 | 1.320 |
Why?
|
| Tachycardia, Ventricular | 11 | 2021 | 60 | 1.290 |
Why?
|
| Body Temperature | 6 | 2021 | 30 | 1.270 |
Why?
|
| Bundle of His | 9 | 2021 | 55 | 1.190 |
Why?
|
| Electrodes | 20 | 2017 | 71 | 1.180 |
Why?
|
| Ganglia, Autonomic | 11 | 2011 | 55 | 1.100 |
Why?
|
| Tachycardia, Supraventricular | 10 | 2018 | 23 | 1.070 |
Why?
|
| Arrhythmias, Cardiac | 15 | 2013 | 163 | 1.000 |
Why?
|
| Animals | 74 | 2021 | 10078 | 0.990 |
Why?
|
| Autonomic Nervous System | 13 | 2012 | 112 | 0.960 |
Why?
|
| Humans | 120 | 2023 | 27115 | 0.940 |
Why?
|
| Atrial Flutter | 6 | 2017 | 13 | 0.920 |
Why?
|
| Heart Ventricles | 13 | 2014 | 133 | 0.910 |
Why?
|
| Action Potentials | 16 | 2018 | 194 | 0.910 |
Why?
|
| Therapeutic Irrigation | 5 | 2012 | 19 | 0.820 |
Why?
|
| Myocardium | 5 | 2021 | 179 | 0.820 |
Why?
|
| Heart Rate | 18 | 2018 | 375 | 0.780 |
Why?
|
| Electrocoagulation | 10 | 1992 | 20 | 0.770 |
Why?
|
| Cryosurgery | 5 | 2018 | 19 | 0.710 |
Why?
|
| Pericardium | 4 | 2014 | 47 | 0.670 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2023 | 171 | 0.640 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 247 | 0.640 |
Why?
|
| Electric Stimulation | 20 | 2011 | 253 | 0.600 |
Why?
|
| Esophagus | 2 | 2008 | 69 | 0.590 |
Why?
|
| Myocardial Infarction | 10 | 2022 | 342 | 0.590 |
Why?
|
| Thrombosis | 5 | 2008 | 147 | 0.590 |
Why?
|
| Middle Aged | 43 | 2020 | 6899 | 0.580 |
Why?
|
| Male | 57 | 2020 | 13019 | 0.570 |
Why?
|
| Disease Models, Animal | 18 | 2021 | 1405 | 0.570 |
Why?
|
| Electrophysiology | 27 | 2012 | 150 | 0.570 |
Why?
|
| Catheterization | 5 | 2007 | 50 | 0.570 |
Why?
|
| Treatment Outcome | 22 | 2022 | 2283 | 0.570 |
Why?
|
| Ganglia, Sympathetic | 2 | 2014 | 8 | 0.560 |
Why?
|
| Steam | 2 | 2014 | 2 | 0.540 |
Why?
|
| Radio Waves | 11 | 1998 | 21 | 0.540 |
Why?
|
| American Heart Association | 7 | 2013 | 21 | 0.530 |
Why?
|
| Female | 55 | 2020 | 14633 | 0.530 |
Why?
|
| Vagus Nerve | 7 | 2020 | 106 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 6 | 2013 | 234 | 0.530 |
Why?
|
| Coronary Vessels | 3 | 2013 | 151 | 0.520 |
Why?
|
| Models, Animal | 7 | 2014 | 129 | 0.510 |
Why?
|
| Ganglia, Parasympathetic | 2 | 2014 | 10 | 0.510 |
Why?
|
| Anti-Arrhythmia Agents | 16 | 2011 | 117 | 0.500 |
Why?
|
| Cardiology | 7 | 2017 | 47 | 0.500 |
Why?
|
| Muscle, Skeletal | 5 | 2008 | 622 | 0.500 |
Why?
|
| Adult | 41 | 2018 | 7490 | 0.490 |
Why?
|
| Heart | 7 | 2010 | 221 | 0.480 |
Why?
|
| Noise | 1 | 2014 | 15 | 0.480 |
Why?
|
| Electroporation | 1 | 2014 | 6 | 0.480 |
Why?
|
| Cardiac Catheters | 1 | 2014 | 9 | 0.470 |
Why?
|
| Follow-Up Studies | 16 | 2013 | 988 | 0.470 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2009 | 70 | 0.470 |
Why?
|
| Advisory Committees | 7 | 2013 | 31 | 0.460 |
Why?
|
| Hot Temperature | 1 | 2014 | 84 | 0.450 |
Why?
|
| Temperature | 7 | 2020 | 207 | 0.450 |
Why?
|
| Heart Diseases | 4 | 2008 | 69 | 0.440 |
Why?
|
| Atrial Function, Right | 2 | 2012 | 4 | 0.440 |
Why?
|
| Papillary Muscles | 1 | 2013 | 14 | 0.430 |
Why?
|
| Aged | 29 | 2020 | 5221 | 0.430 |
Why?
|
| Sinoatrial Node | 5 | 2012 | 16 | 0.420 |
Why?
|
| Postoperative Complications | 4 | 2012 | 605 | 0.420 |
Why?
|
| Vagus Nerve Stimulation | 5 | 2015 | 65 | 0.390 |
Why?
|
| Parasympathetic Nervous System | 5 | 2003 | 17 | 0.390 |
Why?
|
| Time Factors | 14 | 2018 | 1570 | 0.390 |
Why?
|
| Atrial Function | 6 | 2009 | 22 | 0.390 |
Why?
|
| Equipment Design | 10 | 2013 | 211 | 0.390 |
Why?
|
| Monitoring, Intraoperative | 2 | 2008 | 30 | 0.380 |
Why?
|
| Vena Cava, Superior | 6 | 2010 | 27 | 0.380 |
Why?
|
| Thoracoscopy | 4 | 2011 | 7 | 0.350 |
Why?
|
| Epicardial Mapping | 1 | 2009 | 8 | 0.340 |
Why?
|
| Heart Septum | 4 | 2002 | 16 | 0.330 |
Why?
|
| Autonomic Denervation | 4 | 2011 | 19 | 0.330 |
Why?
|
| Ganglion Cysts | 1 | 2009 | 8 | 0.330 |
Why?
|
| Calcium Signaling | 1 | 2009 | 68 | 0.320 |
Why?
|
| Electric Impedance | 5 | 2014 | 30 | 0.320 |
Why?
|
| Tachycardia, Sinus | 2 | 2008 | 8 | 0.320 |
Why?
|
| Esophageal Fistula | 1 | 2008 | 2 | 0.320 |
Why?
|
| Ultrasonic Therapy | 1 | 2008 | 4 | 0.320 |
Why?
|
| Fistula | 1 | 2008 | 17 | 0.310 |
Why?
|
| Burns | 1 | 2008 | 16 | 0.310 |
Why?
|
| Electric Countershock | 6 | 2011 | 29 | 0.300 |
Why?
|
| Algorithms | 4 | 2015 | 422 | 0.300 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 2 | 2020 | 25 | 0.290 |
Why?
|
| Heart Block | 4 | 2011 | 43 | 0.280 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2012 | 43 | 0.280 |
Why?
|
| beta-Alanine | 3 | 2011 | 12 | 0.280 |
Why?
|
| Benzimidazoles | 3 | 2011 | 29 | 0.270 |
Why?
|
| Sodium Chloride | 2 | 2005 | 65 | 0.270 |
Why?
|
| Adolescent | 15 | 2018 | 2988 | 0.250 |
Why?
|
| Epinephrine | 1 | 2005 | 36 | 0.250 |
Why?
|
| Bundle-Branch Block | 4 | 2013 | 29 | 0.240 |
Why?
|
| Patient Selection | 5 | 2012 | 143 | 0.240 |
Why?
|
| Cold Temperature | 1 | 2005 | 34 | 0.240 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 472 | 0.240 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 2021 | 7 | 0.220 |
Why?
|
| Atrial Appendage | 4 | 2011 | 31 | 0.210 |
Why?
|
| Acetylcholine | 6 | 2011 | 73 | 0.210 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 205 | 0.210 |
Why?
|
| Thigh | 4 | 2008 | 39 | 0.200 |
Why?
|
| Societies, Medical | 4 | 2017 | 89 | 0.200 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 73 | 0.190 |
Why?
|
| Risk Factors | 7 | 2018 | 2030 | 0.190 |
Why?
|
| Cicatrix | 3 | 2015 | 12 | 0.190 |
Why?
|
| Disease Management | 5 | 2013 | 85 | 0.190 |
Why?
|
| Incidence | 5 | 2023 | 553 | 0.190 |
Why?
|
| Diverticulum | 2 | 2002 | 6 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 16 | 0.180 |
Why?
|
| Vena Cava, Inferior | 2 | 2000 | 16 | 0.180 |
Why?
|
| United States | 13 | 2013 | 2060 | 0.180 |
Why?
|
| Comorbidity | 3 | 2012 | 252 | 0.170 |
Why?
|
| Critical Pathways | 2 | 2010 | 16 | 0.170 |
Why?
|
| Echocardiography | 4 | 2013 | 108 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 750 | 0.160 |
Why?
|
| Fibrinolytic Agents | 3 | 2022 | 68 | 0.160 |
Why?
|
| Stroke | 1 | 2022 | 241 | 0.160 |
Why?
|
| Unconsciousness | 1 | 1998 | 3 | 0.160 |
Why?
|
| Sinus of Valsalva | 1 | 1998 | 12 | 0.160 |
Why?
|
| Models, Cardiovascular | 4 | 2008 | 46 | 0.160 |
Why?
|
| Propofol | 1 | 1998 | 10 | 0.160 |
Why?
|
| Anesthetics, Intravenous | 1 | 1998 | 14 | 0.150 |
Why?
|
| Ligaments | 2 | 2009 | 22 | 0.150 |
Why?
|
| Porphyrins | 1 | 1998 | 19 | 0.150 |
Why?
|
| Prospective Studies | 8 | 2020 | 1219 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2008 | 508 | 0.150 |
Why?
|
| Atrioventricular Block | 1 | 2018 | 8 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 13 | 0.150 |
Why?
|
| Registries | 2 | 2010 | 383 | 0.150 |
Why?
|
| Autonomic Pathways | 3 | 2008 | 16 | 0.150 |
Why?
|
| Recurrence | 8 | 2018 | 316 | 0.140 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2017 | 12 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2011 | 65 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2012 | 141 | 0.140 |
Why?
|
| Child | 6 | 2001 | 2160 | 0.130 |
Why?
|
| Tricuspid Valve | 1 | 1996 | 24 | 0.130 |
Why?
|
| Research Design | 3 | 2012 | 174 | 0.130 |
Why?
|
| Electrodes, Implanted | 6 | 2007 | 40 | 0.130 |
Why?
|
| Heart Aneurysm | 1 | 1996 | 10 | 0.130 |
Why?
|
| Consensus | 4 | 2018 | 69 | 0.130 |
Why?
|
| Prevalence | 3 | 2012 | 478 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 107 | 0.130 |
Why?
|
| Chi-Square Distribution | 4 | 2005 | 144 | 0.130 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2015 | 1 | 0.120 |
Why?
|
| Thermography | 1 | 2014 | 2 | 0.120 |
Why?
|
| Pre-Excitation, Mahaim-Type | 1 | 1994 | 2 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2012 | 595 | 0.120 |
Why?
|
| Electric Stimulation Therapy | 3 | 2011 | 56 | 0.120 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 104 | 0.110 |
Why?
|
| Heart Injuries | 1 | 2013 | 8 | 0.110 |
Why?
|
| Safety Management | 2 | 2010 | 13 | 0.110 |
Why?
|
| Injections, Intravenous | 5 | 2009 | 65 | 0.110 |
Why?
|
| Dog Diseases | 1 | 1993 | 29 | 0.110 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 12 | 0.110 |
Why?
|
| Thromboembolism | 3 | 2011 | 57 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 811 | 0.110 |
Why?
|
| Pre-Excitation Syndromes | 1 | 1993 | 4 | 0.110 |
Why?
|
| Research Report | 1 | 2013 | 22 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 38 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2022 | 260 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 191 | 0.100 |
Why?
|
| Iron | 1 | 2013 | 107 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 225 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2012 | 17 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2012 | 53 | 0.100 |
Why?
|
| Cholinergic Fibers | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adrenergic Fibers | 1 | 2011 | 8 | 0.090 |
Why?
|
| Muscarinic Antagonists | 2 | 2009 | 14 | 0.090 |
Why?
|
| Foundations | 1 | 2010 | 4 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 31 | 0.090 |
Why?
|
| Myocardial Revascularization | 1 | 2010 | 14 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 466 | 0.090 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 49 | 0.090 |
Why?
|
| Sympathetic Nervous System | 2 | 2008 | 67 | 0.090 |
Why?
|
| Pulmonary Artery | 4 | 2006 | 68 | 0.080 |
Why?
|
| Catheters | 2 | 2020 | 23 | 0.080 |
Why?
|
| Endocardium | 3 | 1997 | 16 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2001 | 1100 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 55 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2022 | 293 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 38 | 0.080 |
Why?
|
| Linear Models | 3 | 2005 | 201 | 0.080 |
Why?
|
| Transducers, Pressure | 1 | 2008 | 2 | 0.080 |
Why?
|
| Esophagitis, Peptic | 1 | 2008 | 5 | 0.080 |
Why?
|
| Ulcer | 1 | 2008 | 5 | 0.080 |
Why?
|
| Optical Fibers | 1 | 2008 | 5 | 0.080 |
Why?
|
| Esophagoscopy | 1 | 2008 | 15 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 75 | 0.080 |
Why?
|
| Ganglia, Spinal | 1 | 2008 | 25 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 1988 | 12 | 0.080 |
Why?
|
| Neurons | 1 | 2010 | 276 | 0.080 |
Why?
|
| Materials Testing | 1 | 2008 | 86 | 0.080 |
Why?
|
| Neural Pathways | 1 | 1989 | 118 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2011 | 63 | 0.080 |
Why?
|
| Atracurium | 1 | 2008 | 3 | 0.080 |
Why?
|
| Anilides | 4 | 1988 | 19 | 0.080 |
Why?
|
| Stellate Ganglion | 1 | 2008 | 21 | 0.080 |
Why?
|
| Coronary Angiography | 2 | 2013 | 150 | 0.080 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2008 | 15 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2008 | 47 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 113 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 44 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2004 | 19 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 57 | 0.070 |
Why?
|
| Atropine | 6 | 2009 | 47 | 0.070 |
Why?
|
| Propranolol | 4 | 2002 | 38 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2007 | 14 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 34 | 0.070 |
Why?
|
| Phrenic Nerve | 1 | 2007 | 22 | 0.070 |
Why?
|
| Dabigatran | 3 | 2011 | 20 | 0.070 |
Why?
|
| Ganglia | 1 | 2006 | 9 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 364 | 0.070 |
Why?
|
| Health Policy | 1 | 2007 | 60 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 190 | 0.070 |
Why?
|
| Carbachol | 1 | 2006 | 18 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2022 | 166 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2007 | 229 | 0.060 |
Why?
|
| Endosonography | 1 | 2005 | 36 | 0.060 |
Why?
|
| Ventricular Function | 3 | 2000 | 25 | 0.060 |
Why?
|
| Catecholamines | 1 | 2005 | 18 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 3 | 1998 | 43 | 0.060 |
Why?
|
| Ventricular Function, Left | 2 | 1997 | 101 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2005 | 23 | 0.060 |
Why?
|
| Amiodarone | 4 | 2010 | 11 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2004 | 23 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 28 | 0.060 |
Why?
|
| Electromagnetic Fields | 1 | 2004 | 14 | 0.060 |
Why?
|
| Colchicine | 1 | 2023 | 15 | 0.050 |
Why?
|
| Perfusion | 3 | 1998 | 43 | 0.050 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2002 | 26 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 39 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2002 | 26 | 0.050 |
Why?
|
| Prognosis | 5 | 2011 | 763 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2003 | 388 | 0.050 |
Why?
|
| In Vitro Techniques | 4 | 2012 | 239 | 0.050 |
Why?
|
| Atrial Premature Complexes | 1 | 2001 | 2 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2020 | 405 | 0.050 |
Why?
|
| Fontan Procedure | 1 | 2001 | 24 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2011 | 14 | 0.040 |
Why?
|
| Ear, External | 1 | 2020 | 11 | 0.040 |
Why?
|
| Interprofessional Relations | 2 | 2010 | 63 | 0.040 |
Why?
|
| Angina Pectoris, Variant | 1 | 1979 | 3 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 1979 | 11 | 0.040 |
Why?
|
| Disopyramide | 3 | 2011 | 10 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2453 | 0.040 |
Why?
|
| Coproporphyrins | 1 | 1998 | 1 | 0.040 |
Why?
|
| Porphobilinogen | 1 | 1998 | 1 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 1979 | 109 | 0.040 |
Why?
|
| Aminolevulinic Acid | 1 | 1998 | 14 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 1998 | 19 | 0.040 |
Why?
|
| Young Adult | 2 | 2018 | 2625 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1999 | 68 | 0.040 |
Why?
|
| Electromagnetic Phenomena | 1 | 1998 | 15 | 0.040 |
Why?
|
| Fluoroscopy | 2 | 1999 | 34 | 0.040 |
Why?
|
| Muscles | 1 | 1998 | 70 | 0.040 |
Why?
|
| Syncope | 2 | 1989 | 10 | 0.040 |
Why?
|
| Europe | 2 | 2007 | 97 | 0.030 |
Why?
|
| Electrosurgery | 1 | 1996 | 15 | 0.030 |
Why?
|
| Propanolamines | 2 | 2009 | 16 | 0.030 |
Why?
|
| Acute Disease | 2 | 2009 | 153 | 0.030 |
Why?
|
| Reaction Time | 1 | 1996 | 94 | 0.030 |
Why?
|
| Hindlimb | 1 | 1995 | 20 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2015 | 14 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 1996 | 92 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 93 | 0.030 |
Why?
|
| Contrast Media | 1 | 2015 | 94 | 0.030 |
Why?
|
| Neural Conduction | 1 | 1994 | 24 | 0.030 |
Why?
|
| Necrosis | 2 | 1998 | 81 | 0.030 |
Why?
|
| Electric Capacitance | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 243 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 1993 | 30 | 0.030 |
Why?
|
| Stroke Volume | 1 | 1994 | 111 | 0.030 |
Why?
|
| Risk | 2 | 2012 | 133 | 0.030 |
Why?
|
| Diltiazem | 1 | 1992 | 5 | 0.030 |
Why?
|
| International Cooperation | 1 | 2012 | 18 | 0.020 |
Why?
|
| Germany | 1 | 2012 | 24 | 0.020 |
Why?
|
| Microelectrodes | 1 | 2011 | 18 | 0.020 |
Why?
|
| Ventricular Fibrillation | 2 | 1982 | 40 | 0.020 |
Why?
|
| Quinidine | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 11 | 0.020 |
Why?
|
| Encainide | 4 | 1988 | 4 | 0.020 |
Why?
|
| Cell Polarity | 1 | 1991 | 22 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2011 | 16 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 278 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1991 | 67 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 144 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1991 | 67 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 204 | 0.020 |
Why?
|
| Antithrombins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 589 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2009 | 9 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 290 | 0.020 |
Why?
|
| Episode of Care | 1 | 2009 | 4 | 0.020 |
Why?
|
| Propafenone | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2009 | 6 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2009 | 35 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2009 | 16 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1988 | 21 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 1988 | 53 | 0.020 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 6 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2008 | 31 | 0.020 |
Why?
|
| Thoracoscopes | 1 | 2007 | 1 | 0.020 |
Why?
|
| Nerve Net | 1 | 2009 | 105 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 411 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 465 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 36 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 64 | 0.020 |
Why?
|
| Antioxidants | 1 | 1988 | 220 | 0.020 |
Why?
|
| Purkinje Fibers | 2 | 1982 | 37 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2005 | 51 | 0.020 |
Why?
|
| Heart Failure | 2 | 2005 | 234 | 0.020 |
Why?
|
| Lung | 1 | 1988 | 363 | 0.020 |
Why?
|
| Pyridinium Compounds | 1 | 2005 | 9 | 0.020 |
Why?
|
| Fluorescence | 1 | 2005 | 48 | 0.020 |
Why?
|
| Photons | 1 | 2005 | 27 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 79 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2005 | 67 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 80 | 0.010 |
Why?
|
| Deafness | 1 | 1984 | 9 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 89 | 0.010 |
Why?
|
| Syndrome | 1 | 1984 | 78 | 0.010 |
Why?
|
| Sympathectomy | 1 | 1984 | 16 | 0.010 |
Why?
|
| Procainamide | 1 | 1983 | 9 | 0.010 |
Why?
|
| Ebstein Anomaly | 1 | 1983 | 10 | 0.010 |
Why?
|
| Jugular Veins | 2 | 1999 | 12 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 398 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 1940 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 2002 | 7 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2000 | 351 | 0.010 |
Why?
|
| Benzofurans | 1 | 1981 | 6 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1982 | 118 | 0.010 |
Why?
|
| Autonomic Nerve Block | 1 | 1981 | 3 | 0.010 |
Why?
|
| Parasympathomimetics | 1 | 1981 | 3 | 0.010 |
Why?
|
| Verapamil | 1 | 1980 | 9 | 0.010 |
Why?
|
| Parasympathectomy | 1 | 1999 | 2 | 0.010 |
Why?
|
| Cervical Plexus | 1 | 1999 | 3 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1999 | 13 | 0.010 |
Why?
|
| Veins | 1 | 2000 | 19 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1999 | 24 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 1999 | 36 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 305 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 846 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 2 | 1988 | 21 | 0.010 |
Why?
|
| Hungary | 1 | 1994 | 5 | 0.010 |
Why?
|
| Mitral Valve Prolapse | 2 | 1982 | 21 | 0.010 |
Why?
|
| Cardiomyopathies | 2 | 1982 | 33 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1988 | 9 | 0.000 |
Why?
|
| Arachidonic Acids | 1 | 1988 | 3 | 0.000 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 1988 | 12 | 0.000 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1988 | 22 | 0.000 |
Why?
|
| Superoxides | 1 | 1988 | 61 | 0.000 |
Why?
|
| Glutathione | 1 | 1988 | 70 | 0.000 |
Why?
|
| Rabbits | 1 | 1988 | 275 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1988 | 355 | 0.000 |
Why?
|
| Suction | 1 | 1983 | 10 | 0.000 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1982 | 12 | 0.000 |
Why?
|
| Aprindine | 1 | 1982 | 1 | 0.000 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1982 | 18 | 0.000 |
Why?
|
| Heart Function Tests | 1 | 1981 | 10 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1981 | 11 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1981 | 15 | 0.000 |
Why?
|
| Death, Sudden | 1 | 1981 | 15 | 0.000 |
Why?
|
| Long-Term Care | 1 | 1981 | 30 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1982 | 220 | 0.000 |
Why?
|